Cozadd Bruce C's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Dec 1, 2025
- Accession no.
- 0001193210-25-000011
- Filed
- Dec 1, 2025
- Trade date
- Nov 26, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $13.8M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cozadd Bruce CCIK 0001193210 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Ordinary Shares | MOption exerciseAcquired | +76,689 | $123.36 | +$9,460,355.04 | 470,021 | Direct | |
| Nov 26, 2025 | Ordinary Shares | MOption exerciseAcquired | +811 | $123.36 | +$100,044.96 | 470,832 | Direct | |
| Nov 26, 2025 | Ordinary Shares | SSaleDisposed | −30,487 | $178.06F1 | −$5,428,515.22 | 440,345 | Direct | |
| Nov 26, 2025 | Ordinary Shares | SSaleDisposed | −8,380 | $179.23F2 | −$1,501,947.4 | 431,965 | Direct | |
| Nov 26, 2025 | Ordinary Shares | SSaleDisposed | −507 | $179.79F3 | −$91,153.53 | 431,458 | Direct | |
| Nov 26, 2025 | Ordinary Shares | SSaleDisposed | −38,126 | $177.27F4 | −$6,758,596.02 | 393,332 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | Ordinary Shares | MOption exerciseDisposed | −811 | $0.00 | $0 | 0 | Direct | |
| Nov 26, 2025 | Ordinary Shares | MOption exerciseDisposed | −76,689 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $177.70 to $178.685. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $178.72 to $179.705. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $179.73 to $179.96. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.70 to $177.69. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.